Home > Publications database > Influence of family history on risk of second primary cancers and survival in squamous cell skin cancer patients. > print

001     148721
005     20240229123033.0
024 7 _ |a 10.1111/bjd.18809
|2 doi
024 7 _ |a pmid:31853941
|2 pmid
024 7 _ |a 0007-0963
|2 ISSN
024 7 _ |a 0366-2845
|2 ISSN
024 7 _ |a 1365-2133
|2 ISSN
024 7 _ |a altmetric:73036928
|2 altmetric
037 _ _ |a DKFZ-2019-03247
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Chattopadhyay, Subhayan
|0 P:(DE-He78)9918be87133a5ff93034e03087506c3c
|b 0
|e First author
|u dkfz
245 _ _ |a Influence of family history on risk of second primary cancers and survival in squamous cell skin cancer patients.
260 _ _ |a Oxford
|c 2020
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1683805681_11662
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Sep;183(3):488-494 / #EA:C050#EA:C020#LA:C050#LA:C020#
520 _ _ |a Squamous cell skin cancer (SCC) patients have excellent prognosis but second primary cancers (SPCs) weaken survival prospects. Family history is a known risk factor for cancer but whether it is a risk factor for SPC in SCC patients is not known.Quantify the risk of family history on SPCs in SCC patients and estimate survival probabilities of patients with SPCs depending on family history.With 13,945 histologically verified SCCs, relative risks (RRs) were estimated for family history using a generalized regression model. For survival analysis, hazard ratios were assessed using a multivariable Cox-proportional hazard model.Family history of invasive SCC increased risk of second invasive SCC, RR = 42.92 (confidence intervals 33.69-50.32) compared to risk without family history RR 19.12 (17.88-21.08). Family history of any non-skin cancer in invasive SCC increased risk of the same cancers to be diagnosed as SPC; RRFH = 1.48 (1.35-1.61) vs. RRno FH = 1.40 (1.32-1.48); significant increases were observed for seven different non-skin cancers. Most results were replicated in in situ SCC. SPC was deleterious for survival irrespective of family history; hazard ratio for patients with SPC was 4.28 (3.83-4.72) compared to those without SPC (1.00).Family history of non-skin cancer was associated with approximately a doubling of risk for SPCs in SCC patients. SPC increases the death rate in SCC patients 3 to 4 times, irrespective of family history. Taking family history into account at SCC diagnosis may help prevention or early detection of SPCs.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Zheng, G.
|0 P:(DE-He78)98a8f1a22ffc460364a8a34499118103
|b 1
|u dkfz
700 1 _ |a Hemminki, A.
|0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
|b 2
|u dkfz
700 1 _ |a Försti, A.
|0 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
|b 3
|u dkfz
700 1 _ |a Sundquist, K.
|b 4
700 1 _ |a Sundquist, J.
|b 5
700 1 _ |a Hemminki, Kari
|0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
|b 6
|e Last author
|u dkfz
773 _ _ |a 10.1111/bjd.18809
|g p. bjd.18809
|0 PERI:(DE-600)2004086-6
|n 3
|p 488-494
|t British journal of dermatology
|v 183
|y 2020
|x 1365-2133
909 C O |p VDB
|o oai:inrepo02.dkfz.de:148721
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)9918be87133a5ff93034e03087506c3c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)98a8f1a22ffc460364a8a34499118103
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRIT J DERMATOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BRIT J DERMATOL : 2017
920 1 _ |0 I:(DE-He78)C050-20160331
|k C050
|l Molekular-Genetische Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 1
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 2
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C050-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21